Catch up on the latest news and comments from the CTAD Conference with Springer Healthcare.
Watch our experts discuss conference highlights [1], with Charlotte Teunissen [2], Craig Ritchie [3] and Suzanne E Schindler.
Breakfast Bites
[4]
CTAD – Breakfast Bite 8 – Journey to a New Era in Alzheimer’s Disease [4]
[5]
CTAD – Breakfast Bite 9 – Journey to a New Era in Alzheimer’s Disease [5]
Read the latest news from the CTAD meeting
- Change to donanemab dosing could reduce ARIA-E rates [6]
- Experts make recommendations on real-world donanemab use [7]
- Real-world evidence supports ‘on label’ lecanemab use for patients with AD [8]
- Discordant CSF/PET amyloid-β result signals need for follow-up before treatment [9]
- Off-target vascular amyloid binding may not explain differences in ARIA-E rates [10]